Meda Pharma Gmbh & Co. Kg

Rottapharm Spa

Meda Ab

Joachim Maus

Istvan Szelenyi

Peter Jurgen Cnota

Joachim Goede

Mario Weingart

Andrea Zanardi

Alessandra Cercaci

Ivan Montaldo

Beatrix Fyrnys

Peter Jürgen Cnota

Ursula Petzold

Torsten Hoffmann

Horst Kastrup

Artur Bauhofer

Peter Juergen Cnota

Hans-Jurgen Tritschler

Kastrup Horst

Bauhofer Artur

Ullrich Munzel

Hans-Joachim Tritschler

The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).

Antimicrobial composition

In a pump cap for a pharmaceutical container, there is an electronic unit adapted to record activation of the pump cap by a user for the release of the contents of the container and release the reporting signals in a wireless manner, and to enable operational energy to come from outside, via an appliance in the form of a personal digital assistant, in a wireless manner, in order to record one or several pump cap activations by a user and the wireless release of the reporting signals from one or more pump cap activations.

Pump cap for a pharmaceutical container, insert for a pump cap for a pharmaceutical container, pharmaceutical container with the pump cap, and computer program product

The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the NOVOLIZER&#xae;.

Methods of treating underlying inflammation from COPD or asthma

The invention relates to novel combinations based on anticholinergics, &#x3b2;-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.

Combination of anticholinergics, &#x3b2;2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases

Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment.

Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases

The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer&#xae;.

Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease

Novel combinations based on anticholinergics, &#x3b2;-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases. A particular combination comprises R,R-glycopyrrolate, rolipram, and budesonide, or physiologically acceptable salts thereof, wherein dosage amounts are such that a synergistic therapeutic effect is achieved.

Combination of R,R-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseases

The invention relates to treating colorectal polyps and precancercerous colorectal changes by topical administration of immunomodulating drugs of the imidazoquinoline family, such as imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine), resiquimod (4-amino-&#x3b1;,&#x3b1;-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), sotirimod (2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine).

Treatment of colorectal polyps with imidazoquinoline derivatives

The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a &#x3b2; mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.

Combination of anticholineric and &#x3b2; mimetics for the treatment of respiratory diseases

The subject of the present invention is to provide a combination of two centrally acting analgesics, flupirtine and tramadol, or their respective pharmaceutically acceptable salts for the treament of pain.

Growing community of inventors

Muhlheim, Germany

Joachim Maus